ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 297

How Useful Is Magnetic Resonance Imaging (MRI) in Monitoring Patients with Myositis?

Nicolo Pipitone1, Antonella Notarnicola2, Arnaldo Scardapane3, Gabriele Levrini4, Lucia Spaggiari5, Florenzo Iannone6, Giovanni Lapadula6, Giulio Zuccoli7 and Carlo Salvarani8, 1Unità di Reumatologia, Reggio Emilia, Arcispedale Santa Maria Nuova, Bari, Italy, 2Karolinska Hospital, Rheumatology Unit, Stockholm, Sweden, 3Radiology, University of Bari, Bari, Italy, 4Arcispedale S Maria Nuova, Reggio Emilia, Italy, 5Radiology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 6Bari University, Rheumatology, Bari, Italy, 7Children's Hospital of Pittsburgh, Pittsburgh, PA, 8Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: dermatomyositis, Magnetic resonance imaging (MRI), myositis and polymyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: MRI is commonly used to assess muscle inflammation in myositis. Muscle edema on fat-suppressed sequences is thought to reflect active inflammation. However, it is unclear how useful MRI is in monitoring patients with myositis, in particular which is its sensitivity to change after treatment onset or intensification. In this study, we aimed to assess changes in the edema of the thigh muscles in a cohort of patients with myositis at their first presentation to our centers (T0) and at follow-up after onset/intensification of immunosuppressive therapy (T1). Ancillary aims were to correlate the extent of muscle edema on MRI with serum creakine kinase (CK) and muscle strength . 

Methods: We enrolled in 2 Rheumatology centers 36 patients, 17 with dermatomyositis (DM) and 19 with polymyositis (PM) diagnosed according to Bohan and Peter criteria. The diagnosis of PM was confirmed by histology in all cases. In all patients, CK was measured, manual muscle test (MMT) was performed, and MRI fat-suppressed sequences were acquired within a week. MRI edema (1= present, 0= absent) was assessed bilaterally in 17 thigh and pelvic floor muscles. An MRI composite edema score (0-17) was calculated by adding the separate scores bilaterally and dividing them by two as described in Clin Exp Rheumatol 2012; 30:570-3. The CK upper limit of normal was 190 U/l. The (single measures) intraclass correlation coefficient (ICC) between the Radiologists involved was 0.78. Muscle strength was measured by MMT and graded according to the Medical Research Council extended scale (0-5). The ICC between the 2 physicians performing the MMT was 0.8. Analysis was performed by Wilcoxon sum rank and Spearman’s tests, as appropriate

Results: Mean age (years±SD) was 54±15. The ratio F:M was 31:5. MRI was positive (edema score equal to, or greater than 1) in 26 (72%) patients at T0 and in 18 (50%) at T1. Mean MRI edema score was 5±5.2 (mean±SD) at T0 and 2.4±4.5 at T1 (p=0.002). Median and interquartile range (IQR) of MRI edema score were 3.5 (8) at T0 and 0.5 (4.5) at T1. CK was elevated in 22 (61%) patients at T0 and 10 (28%) at T1. CK was 1,816±3,560 at T0 and 531±1,536 at T1 (p=0.002). MMT score was 4.4±0.44 at T0 and 4.6±0.40 at T1 (p=0.02). MRI edema score did not correlate with CK or MMT scores neither at T0 nor T1. Eleven patients had a normal CK but a positive MRI at T0. In 5 of these patients, MRI became negative at T1. In the 11 patients with a normal CK but positive MRI at baseline, MRI edema score decreased from 6.7±5.3 at T0 to 2.4±2.7 at T1 (significance not calculated because of the small sample size).

Conclusion: MRI is a useful tool to monitor patients with myositis, and might particularly have a role in monitoring disease activity in patients with a normal serum CK at baseline. Larger studies are required to confirm our findings.


Disclosure: N. Pipitone, None; A. Notarnicola, None; A. Scardapane, None; G. Levrini, None; L. Spaggiari, None; F. Iannone, None; G. Lapadula, None; G. Zuccoli, None; C. Salvarani, None.

To cite this abstract in AMA style:

Pipitone N, Notarnicola A, Scardapane A, Levrini G, Spaggiari L, Iannone F, Lapadula G, Zuccoli G, Salvarani C. How Useful Is Magnetic Resonance Imaging (MRI) in Monitoring Patients with Myositis? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/how-useful-is-magnetic-resonance-imaging-mri-in-monitoring-patients-with-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-useful-is-magnetic-resonance-imaging-mri-in-monitoring-patients-with-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology